Every GLP-1 product NOMIDA LLC lists
One row per product NDC, in FDA’s words. Strength is printed as FDA lists it, spacing tidied.
| Product | Product NDC | Form and strength | FDA category | Listed | Packages |
|---|---|---|---|---|---|
| Semaglutide | 84223-001 | Powder1 mg/mg | Bulk ingredientBULK INGREDIENT | Since Apr 15, 2024Marketing ends May 15, 2027 | 10 packages
|
| Tirzepatide | 84223-002 | Powder1 mg/mg | Bulk ingredientBULK INGREDIENT | Since Apr 15, 2024Marketing ends May 15, 2027 | 4 packages
|
| Liraglutide | 84223-003 | Powder1 kg/kg | Bulk ingredientBULK INGREDIENT | Since Feb 1, 2025Marketing ends May 15, 2027 | 3 packages
|
The rest of its federal record
Checked against every GLP-1 record we publish from FDA. A recall or shortage counts when FDA printed one of this firm’s NDCs in it; a letter or 503B entry counts when the firm name matches exactly. Similar names are listed apart and not counted.
503B outsourcing facility register
Not on the register under this name.
GLP-1 warning letters
None of the GLP-1 warning letters we hold is addressed to this name.
Letters to a similarly named firm: Nomida.biz (Sep 12, 2024). A related company is not necessarily the same legal entity.
GLP-1 recalls
- Class II, ongoing, reported Mar 11, 2026: Lack of Assurance of SterilityD-0392-2026 · New Life Pharma LLC · matched by NDC
- Class II, ongoing, reported Mar 11, 2026: Lack of Assurance of SterilityD-0393-2026 · New Life Pharma LLC · matched by NDC
- Class II, ongoing, reported Mar 11, 2026: Lack of Assurance of SterilityD-0394-2026 · New Life Pharma LLC · matched by NDC
- Class II, ongoing, reported Mar 11, 2026: Lack of Assurance of SterilityD-0395-2026 · New Life Pharma LLC · matched by NDC
FDA enforcement reports, updated by FDA Sep 23, 2026. Every GLP-1 recall
FDA drug shortage list
None of this firm’s NDCs is on FDA’s GLP-1 shortage entries.
FDA drug shortages ↗, updated by FDA Oct 2, 2026.
What these listings mean, and what they do not
- Bulk ingredient. The active ingredient itself, as powder or solution, sold to manufacturers or, where the listing says so, to compounders. A listing tells FDA the firm makes or sells it; it is not an approval of the ingredient or of anything made from it.
A listing is not an approval, and not a quality check. It tells FDA a firm makes, labels or compounds a drug. Whether a product was approved is a question about its application, shown above where there is one. Whether a plant passed inspection is a different record again.
The molecules. Semaglutide is the ingredient in Ozempic, Wegovy, Rybelsus; Tirzepatide is the ingredient in Mounjaro, Zepbound; Liraglutide is the ingredient in Victoza, Saxenda.
“Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
“Assignment of an NDC number does not in any way denote FDA approval of the product.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
“The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗
Related records
Other firms listing semaglutide, tirzepatide and liraglutide
FDA registers on this site
Sources
- FDA NDC directory via openFDA ↗, updated by FDA .
- FDA’s National Drug Code Directory page ↗ for the quoted definitions.
- Read by us Oct 4, 2026. Not medical advice; this page describes filings, not products’ safety.